SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?
16 references·3 citing·55 second hop
Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? (2013)Neglected infectious diseases: Are push a…Incentivizing Innovation: Adding to the Tool Kit (2010)Incentivizing Innovation: Add…The Health Impact Fund: Making new medicines accessible for all. (2008)The Health Impact Fund: Makin…Developing Drugs For Developing Countries (2006)Developing Drugs For Developi…Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness (2006)Advance market commitments fo…Overcoming health-systems constraints to achieve the Millennium Development Goals (2004)Overcoming health-systems con…Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Market Size in Innovation: Th…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Pharmaceuticals and the Developing World (2002)Pharmaceuticals and the Devel…Intellectual Property: When Is It the Best Incentive System? (2002)Intellectual Property: When I…Drug development for neglected diseases: a deficient market and a public-health policy failure (2002)Drug development for neglecte…Citations, family size, opposition and the value of patent rights (2002)Citations, family size, oppos…The determinants of pharmaceutical research and development expenditures (2001)The determinants of pharmaceu…Drugs for neglected diseases: a failure of the market and a public health failure? (2001)Drugs for neglected diseases:…The determinants of pharmaceutical research and development expenditures (2000)The determinants of pharmaceu…How effective are fiscal incentives for R&D? A review of the evidence (2000)How effective are fiscal ince…Patent Buy-Outs: A Mechanism for Encouraging Innovation (1997)Patent Buy-Outs: A Mechanism …Access to science and innovation in the developing world (2025)Access to science and innovat…We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. (2021)We Cannot Win the Access to M…A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines (2019)A re‐evaluation of the framew…Another look at the instrumental variable estimation of error-components models (1995)Initial conditions and moment restrictions in dynamic panel data models (1998)Econometric Analysis of Cross Section and Panel Data (2001)Depression Babies: Do Macroeconomic Experiences Affect Risk Taking?* (2011)What Determines Productivity? (2011)Carbon Taxes, Path Dependency, and Directed Technical Change: Evidence from the Auto Industry (2016)Assessing aid - what works, what doesn't, and why (1998)Assessing Aid: What Works, What Doesn't, and Why (1999)The Millennium Development Goals for Health (2004)Antecedents of bridge employment: A longitudinal investigation. (2008)Health systems financing and the path to universal coverage (2010)Improving immunisation coverage in rural India: clustered randomised controlled evaluation of immunisation campaigns with and without incentives (2010)A Penny for Your Quotes: Patent Citations and the Value of Innovations (1990)Patent Statistics as Economic Indicators: A Survey (1990)Geographic Localization of Knowledge Spillovers as Evidenced by Patent Citations (1993)Handbook of Quantitative Science and Technology Research (2005)Technological Innovation, Resource Allocation, and Growth* (2017)Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)Access to Essential Drugs in Poor Countries (1999)A New Trade Framework for Global Healthcare R&D (2004)The Pharmaceutical Commons (2014)Market Failures and Market Framings: Can a market be transformed from the inside? (2017)Cost of innovation in the pharmaceutical industry (1991)Stocks, bonds, bills, and inflation yearbook (1993)Risks in new drug development: Approval success rates for investigational drugs (2001)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The Changing Relation between Mortality and Level of Economic Development (1975)The Role of Wages and Auditing during a Crackdown on Corruption in the City of Buenos Aires (2003)The Determinants of Mortality (2006)Compulsory Licensing: Evidence from the Trading with the Enemy Act (2009)Why Working from Home Will Stick (2021)Human Development Report 2001: Making new technologies work for human development (2001)Intellectual property rights, the WTO and developing countries: the TRIPS agreement and policy options (2001)25 years of the WHO essential medicines lists: progress and challenges (2003)HUMAN RIGHTS AND GLOBAL HEALTH: A RESEARCH PROGRAM (2005)The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment (2013)Capitalism, Socialism and Democracy (1997)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)Assessing the impact of organizational practices on the relative productivity of university technology transfer offices: an exploratory study (2002)Against Intellectual Monopoly (2008)Sequential innovation, patents, and imitation (2009)A Model of Growth Through Creative Destruction (1990)A Model of Growth Through Creative Destruction (1992)Do Scientists Pay to Be Scientists? (2004)Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis (2005)Do formal intellectual property rights hinder the free flow of scientific knowledge? (2007)Review of Economic Studies (2010)Tax Policy and Investment Behavior (1967)The Taxation of Income from Capital (1984)R & D and Internal Finance: A Panel Study of Small Firms in High-Tech Industries (1994)The Stock Market Valuation of Research and Development Expenditures (2001)The Financing of Research and Development (2002)The Financing of R&D and Innovation (2010)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,312 cited
  • 2002Citations, family size, opposition and the value of patent rights1,510 cited
  • 2000How effective are fiscal incentives for R&D? A review of the evidence1,014 cited
  • 2004Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry971 cited
  • 2002Drug development for neglected diseases: a deficient market and a public-health policy failure895 cited
  • 2004Overcoming health-systems constraints to achieve the Millennium Development Goals858 cited
  • 1997Patent Buy-Outs: A Mechanism for Encouraging Innovation497 cited
  • 2002Intellectual Property: When Is It the Best Incentive System?376 cited
  • 2002Pharmaceuticals and the Developing World323 cited
  • 2001Drugs for neglected diseases: a failure of the market and a public health failure?228 cited
  • 2006Developing Drugs For Developing Countries198 cited
  • 2008The Health Impact Fund: Making new medicines accessible for all.187 cited
  • 2006Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness120 cited
  • 2000The determinants of pharmaceutical research and development expenditures109 cited
  • 2001

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

The determinants of pharmaceutical research and development expenditures
97 cited
  • 2010Incentivizing Innovation: Adding to the Tool Kit96 cited
  • Cited by

    • 2021We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis.47 cited
    • 2019A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines7 cited
    • 2025Access to science and innovation in the developing world4 cited